Efficacy and Safety of Oral Small Molecule Glucagon-Like Peptide 1 Receptor Agonist Danuglipron for Glycemic Control Among Patients With Type 2 Diabetes: A Randomized Clinical Trial

IMPORTANCE: Currently available glucagon-like peptide 1 receptor (GLP-1R) agonists for treating type 2 diabetes (T2D) are peptide agonists that require subcutaneous administration or strict fasting requirements before and after oral administration. OBJECTIVE: To investigate the efficacy, safety, and...

Descripción completa

Detalles Bibliográficos
Autores principales: Saxena, Aditi R., Frias, Juan P., Brown, Lisa S., Gorman, Donal N., Vasas, Szilard, Tsamandouras, Nikolaos, Birnbaum, Morris J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2023
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10203889/
https://www.ncbi.nlm.nih.gov/pubmed/37213102
http://dx.doi.org/10.1001/jamanetworkopen.2023.14493

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10203889/
https://www.ncbi.nlm.nih.gov/pubmed/37213102
http://dx.doi.org/10.1001/jamanetworkopen.2023.14493

Ejemplares similares